GSK announces changes to Corporate Executive Team

GSK announces changes to Corporate Executive Team

Issued: 30th April 2008, London, UK and Philadelphia, USA

GlaxoSmithKline (GSK) today announced a number of changes to its Corporate Executive management team. In a message to employees, Andrew Witty, CEO designate, detailed new appointments and his new management team which will take effect on 22nd May when he assumes the role of Chief Executive Officer.

Outlining the context for these changes, Andrew Witty said: “It is clear that our industry is facing a rapidly changing environment. Demand for innovative medicines and healthcare products continues to grow, however we are also presented with increasing challenges, such as cost containment, regulatory pressures and generic competition.”

To address these challenges, Witty stated that the company must work hard to increase GSK’s global reach and presence, and ensure that vaccines, consumer healthcare and pharmaceuticals all play their full potential. He emphasised the need for GSK’s business regions to drive sales growth, and announced new operational structures to expand and improve GSK’s capability, particularly in emerging markets and in Asia.

“Emerging markets, such as Brazil, Russia, India, China and the Middle East, are significant growth drivers of the future. They are already contributing close to 25% of today's market growth and are forecast to grow even faster in the future, around triple the rate of western countries. It is essential that we have an operating structure that is dynamic and responsive to the opportunities in these markets,” said Witty.

“I am therefore creating a new Emerging Markets region which will ensure that we devote the focus required to build on our excellent foundations in those markets and truly establish ourselves as a trusted, long-term partner, one that is actively working to address the specific healthcare needs in those countries,” he said.

A new Asia Pacific region will also be created, which includes Japan and Australia. Witty noted that many of these countries have sophisticated and well-organised healthcare systems and that these markets represent ‘significant and immediate opportunities’ for existing products and products which will be launched over the next few years.

As part of the changes to business regions, GSK has also realigned markets in North America (combining the US, Canadian and Puerto Rican businesses) and has established new operational areas in Europe to maximise their potential and opportunities for growth.

Witty also placed emphasis on the development of GSK’s business through partnership and collaboration, and announced a new dedicated team for Corporate Strategy and Development:

"Making the changes required to develop our business for the next decade requires a rigorous and disciplined focus on corporate strategy. A key element of this new team’s remit will be to proactively seek new business opportunities to expand our global reach and drive sales growth,” he said.

Finally, Witty also spoke to measures to improve processes and ensure that the company works effectively and efficiently. He also placed great emphasis on the need to sustain and develop the strong ethical culture of GSK:

“Ultimately, our culture and our people will be the key factors in our success. We need to ensure that we always do what is right for the patients and I want GSK to meet the highest standards expected of us by society,” said Witty.

GSK Corporate Executive Team (effective May 22nd 2008):

Andrew Witty, Chief Executive Officer*
Julian Heslop, Chief Financial Officer*
Moncef Slaoui, Chairman, Research & Development*
Chris Viehbacher, President, North American Pharmaceuticals*
Simon Bicknell, SVP, Company Secretary & Compliance Officer
John Clarke, President, Consumer Healthcare
Marc Dunoyer, President, Asia Pacific/Japan
Eddie Gray, President, Pharmaceuticals Europe
Abbas Hussain, President, Emerging Markets. Abbas will join GSK on 2 June from Eli Lilly and Company, where he has spent 20 years overseeing markets throughout Europe, Africa/Middle East and Australasia
Duncan Learmouth, SVP, Corporate Communications & Global Community Partnerships
Bill Louv, Chief Information Officer
Dan Phelan, Chief of Staff
David Pulman, President, Global Manufacturing & Supply
David Redfern, Chief Strategy Officer
Jean Stéphenne, President and General Manager, Biologicals
Claire Thomas, SVP, Human Resources
SVP & General Counsel (currently vacant)
* Executive directors who are also members of GSK's Board of Directors

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

 

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.